Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Blood / Hematology News

Cubist Pharmaceuticals Initiates Phase 2 Trial In Europe For Therapy To Reduce Blood Loss During Surgery In High Risk Patients

Main Category: Blood / Hematology
Also Included In: Clinical Trials / Drug Trials
Article Date: 08 Jul 2009 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions




Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), a leading acute care therapeutics company, announced that it has begun dosing in the CONSERV™-2 clinical trial with ecallantide. CONSERV-2, being conducted in Europe, is a Phase 2 trial that will investigate ecallantide's effect on surgical blood loss volume in cardiac surgery patients who are on cardiopulmonary bypass and are at a high risk of bleeding. The trial is expected to enroll 300 subjects.

Ecallantide is a potent inhibitor of plasma kallikrein, and CONSERV-2 will evaluate the effects of plasma kallikrein inhibition in the trial population. Surgical environments, such as those involving the trial population, are associated with the activation of plasma kallikrein and subsequent activation of coagulation, fibrinolytic, and inflammatory cascades, which likely contribute to blood loss and blood transfusion requirements in the perioperative setting.

"The dosing of patients in the CONSERV-2 trial represents another important milestone in the continued evaluation of ecallantide for the reduction of blood loss during on-pump cardiac surgery, an area of significant unmet medical need. We remain on track for a mid-2010 end-of-phase 2 meeting with the FDA, and we anticipate that the results of this trial and the ongoing CONSERV-1 trial will provide meaningful insights into the optimal design of subsequent Phase 3 trials," said Santosh Vetticaden, PhD, MD, Senior Vice President, Clinical Development and Chief Medical Officer.

"This represents another important milestone for our growing pipeline of novel acute care therapeutics" said Steve Gilman, PhD, Chief Scientific Officer and Senior Vice President, Discovery and Nonclinical Development.

In April 2008, Cubist announced an exclusive North American and European license and collaboration agreement with Dyax Corp. (NASDAQ: DYAX) for the development and commercialization of the intravenous formulation of ecallantide for surgical indications. The first indication being sought by Cubist for ecallantide is the reduction of blood loss during on-pump cardiac surgery.

Source
Cubist Pharmaceuticals, Inc.




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Haiti Appeal

Haiti Appeal Image
The severe earthquake that struck Haiti has inflicted damage and devastation on a massive scale. Please donate to the Doctors Without Borders Haiti Appeal.

PLEASE DONATE HERE


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is a Nosebleed? What Causes Nosebleeds?
22 Sep 2009
The medical term for nosebleed is epistaxis. We can also say nasal hemorrhage. The human nose, and those of many animals are rich in blood vessels. Because of the position of the nose - right in the middle of the face - and...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

Keeping a Personal Medical Record image Keeping a Personal Medical Record

Medical information is usually scattered in many different places. To receive the best possible health care, people are encouraged to gather information in one place and create a personal medical record...

View more videos...